ClinicalTrials.gg
RecruitingNCT069793628212-PreservedUpdated Oct 5, 2026

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

A Phase 2 interventional study of CDR132L and Placebo in Heart Failure, sponsored by Novo Nordisk A/S. Recruiting at 118 sites in 9 countries. Open to participants aged 40 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Oct 5, 2026Eligibility revisedSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
40 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.

Planned enrollment
5th of 11
200 · median 200
Started
2025
with 4 others
Phase 2
4 of 14
2 open now
Registered
9th of 14
by date

Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 2, and was the 9th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
40 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-84 years (both inclusive) at the time of signing the
  • Documented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and/or a sodium-glucose cotransporter-2 inhibitor (SGLT2i), and class II-III at screening
  • Clinically stable and on optimised doses and unchanged drug classes of guideline-directed HF therapy ≥45 days prior to randomisation
  • ≥40% as assessed by echocardiography at screening, measured by central laboratory
  • Left ventricular hypertrophy assessed by echocardiography at screening measured by central laboratory with any of the following:

    1. LVMi (greater than) >88 gram per square meter (g/m\^2) for female participants and >102 g/m\^2 for male participants, using the truncated ellipsoid method measured by central laboratory
    2. LVMi >95 g/m2 for female participants and >115 g/m2 for male participants using the linear method (cube formula).
    3. Interventricular septum diameter measured in diastole (IVSd) in the parasternal long axis view ≥1.1 cm for female participants and ≥1.2 cm for male participants.
  • 18.5-45 kilogram per square meter (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1)
  • NT-proBNP ≥300 picograms per milliliter (pg/mL); NT-proBNP ≥600 pg/mL if atrial fibrillation/flutter is present at time of screening, measured by central laboratory

Exclusion criteria

Exclusion Criteria:

  • Estimated lesser than (\<) 30 milliliter per minute (mL/min)/1.73 square meter (m\^2) at time of screening, measured by central laboratory
  • Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator, within 90 days prior to randomisation
  • Myocardial infarction, unstable angina pectoris or HF hospitalisation within 30 days prior to screening
  • Participants receiving intravenous HF medications within 45 days prior to randomisation
  • Participants with CRT, pacemaker or implantable cardioverter-defibrillator
  • Planned coronary revascularisation, pacemaker/cardioverter-defibrillator/CRT implantation, ablation of cardiac arrythmias and valve repair/replacement at the time of randomisation
  • Stroke or within 12 months prior to randomisation
  • Participants with potential disruption of the blood-brain barrier (e.g., multiple sclerosis), in the opinion of the investigator
  • Known history of severe liver disease and/or or aspartate aminotransferase >2.5 x at screening, measured by central laboratory
  • Known genetic (or highly suspected due to family history) cause of increased cardiac mass (including dilated cardiomyopathy, Fabry disease and likely pathogenic or pathogenic variants within hypertrophic cardiomyopathy [HCM]).
  • Participants with suspected or diagnosed cardiac amyloidosis or sarcoidosis.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    CDR132L: Dose 1

    Participants will receive intravenous infusion of CDR132L dose 1 once every 4 weeks for 48 weeks. Participants will also continue their individually adapted guideline-directed Standard of care (SoC) therapy for heart failure.

    Drug: CDR132L

  • Experimental
    CDR132L: Dose 2

    Participants will receive intravenous infusion of CDR132L dose 2 once every 4 weeks for 48 weeks. Participants will also continue their individually adapted guideline-directed SoC therapy for heart failure.

    Drug: CDR132L

  • Experimental
    CDR132L: Dose 3

    Participants will receive intravenous infusion of CDR132L dose 3 once every 4 weeks for 48 weeks. Participants will also continue their individually adapted guideline-directed SoC therapy for heart failure.

    Drug: CDR132L

  • Placebo comparator
    Placebo

    Participants will receive intravenous infusion of placebo once every 4 weeks for 48 weeks. Participants will also continue their individually adapted guideline-directed SoC therapy for heart failure.

    Drug: Placebo

Interventions

  • CDR132L will be administered intravenously once every 4 weeks.

  • DrugPlacebo

    Placebo will be administered intravenously once every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Main phase: Change in normalised microRNA-132-3p (miR-132)

    Measured as ratio to baseline.

    Time frame: From baseline to week 24

Secondary outcomes

  1. Main phase: Composite Z-score based on changes in the 3 outcome measures LVMi (CMR), LAVi (CMR) and NT-proBNP

    The composite Z-score is calculated as the mean of the participant's 3 Z-scores for the change in the 3 outcome measures: left ventricular mass indexed to body surface area \[LVMi (Cardiovascular Magnetic Resonance \[CMR\])\], left atrial volume indexed to body surface area \[LAVi (CMR)\] and N-terminal pro B-type natriuretic peptide (NT-proBNP).

    Time frame: From baseline to week 24

  2. Main phase: Change in normalised miR-132

    Measured as ratio to baseline.

    Time frame: From baseline to week 24

  3. Main phase: Number of adverse events

    Measured as count of events.

    Time frame: From baseline to week 24

  4. Extension phase: Number of adverse events

    Measured as count of events.

    Time frame: From baseline to week 60

07

Study locations

78 of 118 sites recruiting

Showing the first 100 of 118 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2027, 28 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 28 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 19, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Nov 16, 2027
CompletionEst.
Jul 25, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • Amarillo Medical Specialists · Amarillo, United StatesNot yet recruiting→Recruiting
  • IUCPQ - Universite Laval · Québec, CanadaNot yet recruiting→Recruiting
  • Charité - Campus Benjamin Franklin - Klinik für Kardiologie · Berlin, GermanyNot yet recruiting→Recruiting
  • Ome medical center_Cardiology · Ome-shi, Tokyo, JapanNot yet recruiting→Recruiting
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie · Krakow, PolandNot yet recruiting→Recruiting
  • Hosp. U Gran Canaria Dr. Negrín_Cardiologia · Las Palmas de Gran Canaria, SpainNot yet recruiting→Recruiting
  • Hospital Ramón y Cajal_Cardiología · Madrid, SpainNot yet recruiting→Recruiting
Show site
  • Fukuokaken Saiseikai Futsukaichi Hospital_Cardiology · Chikushino-shi, Fukuoka, Japan
Sep 30, 2026
Eligibility
3 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedDocumented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and/or a sodium-glucose cotransporter-2 inhibitor (SGLT2i), and New York Heart Association class II-III at screening
  • EditedLeft ventricular ejection fraction ≥5040% as assessed by echocardiography at screening, measured by central laboratory
  • EditedBody mass index 18.5-4045 kilogram per square meter (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1)
Oct 5, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedMain phase: Change in compositeComposite Z-score based on changes in the 3 outcome measures LVMi (CMR), LAVi (CMR) and NT-proBNPTime frame: From baseline to week 24
Oct 5, 2026
Show all 2 updates
  1. Oct 5, 2026
    Eligibility 3 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedDocumented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and/or a sodium-glucose cotransporter-2 inhibitor (SGLT2i), and New York Heart Association class II-III at screening
    • EditedLeft ventricular ejection fraction ≥5040% as assessed by echocardiography at screening, measured by central laboratory
    • EditedBody mass index 18.5-4045 kilogram per square meter (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedMain phase: Change in compositeComposite Z-score based on changes in the 3 outcome measures LVMi (CMR), LAVi (CMR) and NT-proBNPTime frame: From baseline to week 24
  2. Sep 30, 2026
    1 site added. 7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • Amarillo Medical Specialists · Amarillo, United StatesNot yet recruiting→Recruiting
    • IUCPQ - Universite Laval · Québec, CanadaNot yet recruiting→Recruiting
    • Charité - Campus Benjamin Franklin - Klinik für Kardiologie · Berlin, GermanyNot yet recruiting→Recruiting
    • Ome medical center_Cardiology · Ome-shi, Tokyo, JapanNot yet recruiting→Recruiting
    • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie · Krakow, PolandNot yet recruiting→Recruiting
    • Hosp. U Gran Canaria Dr. Negrín_Cardiologia · Las Palmas de Gran Canaria, SpainNot yet recruiting→Recruiting
    • Hospital Ramón y Cajal_Cardiología · Madrid, SpainNot yet recruiting→Recruiting
    Show site
    • Fukuokaken Saiseikai Futsukaichi Hospital_Cardiology · Chikushino-shi, Fukuoka, Japan
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06979362
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 19, 2025
Start date
Jun 27, 2025
Primary completion
Nov 16, 2027 (estimated)
Completion
Jul 25, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDR132L

Start the discussion